NYSE: DOCS

Doximity (DOCS) Stock Analysis & Forecast

Nov 13 close

$33.34+0.14 (+0.4%)

Gekko Brief

AI summaryNov 9 close

This week's news on Doximity centers on a wave of securities class action lawsuit reminders, with multiple law firms, including Bronstein Gewirtz & Grossman, Bragar Eagel & Squire, Kaplan Fox, Rosen Law Firm, and SBS Law, pointing investors toward a November 16, 2026 lead plaintiff deadline. The underlying claims concern alleged misrepresentations between August 8, 2024 and May 13, 2026 about revenue growth, market share, the Newsfeed product's impact, decelerating sales, contracting net income, and shifts in pharmaceutical advertising budget deployment.

Shares closed at $32.87, up 1.1%, sitting above both the 50-day average of $29.22 and the 200-day average of $25.32, with the 50-day above the 200-day. The GekkoIndex reads 54, placing the stock in the Neutral zone. Price stands 14.4% above Gekko Fair Value of $28.72. One-month return is 7.8%, three-month 25.9%, six-month 25.2%, while the one-year return remains negative at -47.5%.

The next earnings date falls on 4 February 2027, 86 days out and outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the recent windows. Seasonality data covering 5 years shows the next 20 trading days averaging an 11.1% return, with gains in 3 of those years. Analyst consensus among 13 firms includes 4 buy, 7 hold, and 2 sell ratings, with a consensus target of $31.11, implying -5.4% versus the current price.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Doximity price vs fair value

$33.34$28.47Nov ’25May ’26Nov ’26
Close $33.34200-day averageGekko Fair Value $28.47

Doximity quick facts

Market cap
$5.94B
P/E ratio
46.1
Forward P/E
24.7
EPS, TTM
$0.72
Revenue, TTM
$661.6M
Profit margin
21.1%
Dividend yield
—
Beta
1.29
Volume
1.40M avg 2.44M
1-year return
−34.6%
Typical daily move
±4.5%
Typical 20-day move
±10.6%
50-day average
$29.73
200-day average
$25.20
Next earnings
Feb 4 after close
Shares outstanding
127.5M
52-week range
$17.15$51.85

Doximity swing-trade checklist

Doximity scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive1 mixed2 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $33.34 is above the 50-day ($29.73) and 200-day ($25.20) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    53.6, Neutral

    Reading 53.6 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    17.1% above

    Price is 17.1% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 81 days

    Next report Feb 4, 2027, 81 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −3.9% on average

    From this point in the calendar, the next 20 trading days averaged −3.9% over 5 years, rising in 1 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Doximity stock chart and price history

Doximity closed at $33.34 on Nov 13, 2026, −34.6% over the past year, inside a 52-week range of $17.15 to $51.85.

Close50-day average200-day averageVolume
Doximity share price, past year, with 50-day and 200-day moving averages and volume$20$30$40$50$60$70DecJan 2026FebMarAprMayJunJulAugSepOctNov33.34

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+5.8%
3 months
+36.0%
6 months
+75.8%
1 year
−34.6%
The full DOCS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DOCS in Gekko

Follow Doximity through every session

Put DOCS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track DOCS in GekkoFree for 7 days. No credit card required.

About Doximity

Doximity runs a cloud-based digital platform built for healthcare practitioners across the United States. Members use it to connect with fellow professionals, coordinate patient care, hold remote consultations, keep up with medical news and research, and support their career development. The platform is best known as a networking and productivity hub for doctors and other clinicians.

The company draws its business primarily from pharmaceutical companies and healthcare organizations, which make up its main customer base. This positions Doximity as a service provider to institutions within medicine rather than a direct-to-consumer product, with its tools built around the daily needs of practicing clinicians.

Doximity was founded in 2010, originally under the name 3MD Communications, Inc., before adopting its current name later that same year. The company is headquartered in San Francisco, California. Its shares are listed on the NYSE under the ticker DOCS.

Listed
NYSE
Sector
Technology services
Industry
Packaged software
Website
doximity.com

Doximity GekkoIndex: the smart money zone

Doximity’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.6, in the Neutral zone, down 0.4 points over five sessions.

010053.6Neutral

Down 0.4 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying70−1.5%−0.5%−0.7%−7.0%
Accumulation202+1.0%−0.2%−2.0%−4.4%
Neutral (current zone)380+0.7%+2.0%+4.8%+11.2%
Distribution39+0.2%+0.3%−2.4%+7.1%
Selling11−6.2%−11.6%−8.7%−14.9%

Average DOCS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the DOCS price, zone by zone.Track DOCS in Gekko

Is Doximity stock overvalued? Gekko Fair Value

Doximity trades 17.1% above Gekko Fair Value of $28.47, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Doximity shares are worth, recalculated every trading day.

$28.47

Gekko Fair Value, Nov 14, 2026

17.1% Overvalued

At the end of Aug 2026 the price was 3.8% below the estimate.

Gekko Fair ValueShare price, month end
$28$33Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open DOCS in Gekko

Doximity insider and Congress trading

No open-market insider purchases were filed for Doximity, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for DOCS in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every DOCS insider filing, plotted on the chart in Gekko.Open DOCS in Gekko

Congress trades last 90 days

No trades in DOCS were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for DOCS, plotted on the chart in Gekko.Open DOCS in Gekko

Buybacks

Doximity has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$54.20M
As a share of market cap
0.91%
Trailing four quarters
$433.2M

From company filings.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds DOCS.

0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Doximity earnings: next date and track record

Doximity reports on Feb 4, 2027, after the close (81 days away), and beat the EPS estimate in 6 of its last 8 reports.

6 of 8reports beat the EPS estimate
±24.4%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+37.5%Nov ’24+36.3%Feb ’25−11.7%May ’25+14.5%Aug ’25−15.2%Nov ’25−21.3%Feb ’26−31.9%May ’26+26.6%Aug ’26

Last earnings call, Aug 6, 2026 AI summary

What they said
Doximity reported a strong Q1 FY2027: revenue of $157M, up 7% year-over-year, and adjusted EBITDA of $75M (48% margin), both beating the high end of guidance. Management emphasized that FY2027 is an "AI investment year," expanding AI spending while maintaining high software margins. The company highlighted independent validation (NOHARM study) showing Doximity Ask leading U.S. models on clinical accuracy and safety, attributing outperformance to a proprietary drug reference and 12,000 physician PeerCheck editors. AI product momentum (Ask, AI search, and Scribe) drove higher usage and engagement, accelerating prompts and onboarding of initial AI search customers (a couple dozen programs), with expectations that most contracted AI search revenue to date will be recognized in Q3. The sales mix remained concentrated: 127 pharma and hospital customers generate >$500k ARR (83% of revenue); top 20 NRR was 112% and overall NRR 107% (TTM). Management signaled confidence in the long-term TAM and unit economics of AI search (stated >10x revenue per search vs cost today) and described strong pipeline activity across pharma, hospitals, and SMBs, while acknowledging a still-tight but stabilizing buying environment.
Guidance
Q1 results beat guidance. Management indicated revenue guidance to grow around 5% for the rest of FY2027. They expect the majority of AI search revenue contracted to date to be recognized in Q3 of FY2027. Management also stated they will expand AI investment in FY2027 (an "AI investment year").
Risks flagged
Legal and regulatory risk around clinical AI (lawsuits and AI steering committee concerns); tight macro/budget environment for buyers (though stabilizing); customer concentration risk (large customers account for a high share of revenue); execution risks related to product rollout, EHR integrations and monetization timing; potential reputational risk if AI outputs produce clinical errors.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 6, 2026$0.14
est $0.16
−12.5%$156.6M
est $151.8M
+3.2%+26.6%
May 13, 2026$0.26
est $0.28
−7.1%$145.4M
est $144.0M
+0.9%−31.9%
Feb 5, 2026$0.46
est $0.45
+2.2%$185.1M
est $181.6M
+1.9%−21.3%
Nov 6, 2025$0.45
est $0.38
+18.8%$168.5M
est $157.9M
+6.7%−15.2%
Aug 7, 2025$0.36
est $0.30
+19.4%$145.9M
est $139.5M
+4.6%+14.5%
May 15, 2025$0.38
est $0.27
+39.9%$138.3M
est $133.7M
+3.4%−11.7%
Feb 6, 2025$0.45
est $0.31
+45.2%$168.6M
est $134.1M
+25.7%+36.3%
Nov 7, 2024$0.30
est $0.25
+20.0%$136.8M
est $127.1M
+7.6%+37.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Doximity stock forecast and analyst price targets

Analysts’ average 12-month price target for Doximity is $31.50, −5.5% from the last close, from 13 firms rating the stock in the last 90 days.

$31.50consensus 12-month target, −5.5% from the last close
Low $18High $40
Buy4
Hold7
Sell2

Each firm’s latest rating in the last 90 days: 13 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 11BarclaysHold, maintained$30−10.0%
Nov 10BarclaysHold, maintained$30−10.0%
Nov 9Morgan StanleyBuy, reiterated$35+5.0%
Nov 9Canaccord GenuityBuy, reiterated$40+20.0%
Nov 8BTIGHold, maintained——
+4.8%average 20-day move after past Neutral readings
−3.9%average move over the next 20 trading days in the last 5 years
±4.5%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Doximity seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Doximity averaged −3.9% across the last 5 years, rising in 1 of them.

Next 20 trading days, by year

−24.9%2021+18.6%2022−2.9%2023+0.2%2024−10.0%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−5.0%2 of 5
Next 10 trading days−0.5%3 of 5
Next 15 trading days−2.3%2 of 5
Next 20 trading days−3.9%1 of 5
Next 30 trading days−2.3%3 of 5

For scale, DOCS’s typical 20-trading-day move in either direction is about 10.6%.

Doximity market cap and key statistics

Doximity’s market cap is $5.94B, with a P/E ratio of 46.1 and revenue of $661.6M over the last twelve months.

Valuation

Market cap
$5.94B
P/E ratio
46.1
Forward P/E
24.7
EPS, TTM
$0.72
Gekko Fair Value
$28.47

Trading

Volume
1.40M
Avg volume, 20 days
2.44M
52-week high
$51.85
52-week low
$17.15
Shares outstanding
127.5M

Financials

Revenue, TTM
$661.6M
Profit margin
21.1%
Return on equity
13.8%
Quarterly earnings growth, YoY
−41.9%

Risk and income

Beta
1.29
Typical daily move
±4.5%
Typical 20-day move
±10.6%

Doximity peers

Doximity’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
MSFTMicrosoft+0.8%Neutral10.6% above
PLTRPalantir Technologies−2.2%Accumulation8.2% below
ORCLOracle−1.7%Neutral27.9% below
PANWPalo Alto Networks−2.5%Accumulation0.6% above
CRWDCrowdStrike−4.0%Accumulation0.9% above
CRMSalesforce−1.0%Accumulation12.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Packaged software

Doximity stock FAQ

What is Doximity’s market cap?

Doximity’s market cap is $5.94B at the Nov 13, 2026 close of $33.34, with 127.5M shares outstanding. The shares trade on a P/E ratio of 46.1.

What is the Doximity stock forecast?

The consensus analyst 12-month price target for Doximity is $31.50, −5.5% from the last close. Of the 13 firms that rated the stock in the last 90 days, 4 rate it a buy, 7 a hold and 2 a sell. Gekko doesn’t publish price predictions of its own.

Is Doximity stock overvalued or undervalued?

On Gekko’s estimate Doximity is overvalued: the Nov 13, 2026 close of $33.34 is 17.1% above Gekko Fair Value of $28.47. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Doximity report earnings next?

Doximity is expected to report on Feb 4, 2027, after the market closes (81 days away). Analysts expect earnings of $0.41 per share on revenue of $195.8M. Doximity beat the earnings estimate in 6 of its last 8 reports, moving 24.4% on average across the report.

What is Doximity’s 52-week high and low?

Doximity’s 52-week high is $51.85 and its 52-week low is $17.15; it closed at $33.34 on Nov 13, 2026, −34.6% over the past year. Over the last five years the shares peaked at $85.21 on Feb 10, 2025.

Is Doximity stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Doximity the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.